"Certainly, I've been anxious about data...I did an experiment, I put a lot of time into it, I'm hoping to get good results...we all know that feeling, right? The stakes are just so different here...this kid's life depends on whether this experiment worked."

--Kiran Musunuru, MD, PhD

One of the highlights of the ASGCT 28th Annual Meeting was the announcement on May 15 of a historic medical breakthrough: a child diagnosed with a rare genetic disorder had been successfully treated for the first time with a customized CRISPR gene editing therapy.

The infant, KJ Muldoon, was born with a rare metabolic disease called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. When he was just six months old, KJ received his personalized therapy at the Children's Hospital of Philadelphia (CHOP), where ASGCT Members Kiran Musunuru, MD, PhD; and Rebecca Ahrens-Nicklas, MD, PhD; led the group of researchers who developed KJ's treatment.

KJ is now growing and thriving. He recently left the hospital where he has spent the majority of his life. And the day after presenting the research that led to this first-of-its-kind development, Dr. Musunuru told us that there was so much more to the story.

Listen to our first episode of Soundbites of the Annual Meeting with Dr. Kiran Musunuru. 

Did you attend the 28th Annual Meeting?
Watch all sessions, including Dr. Musunuru's presentation, on demand on the virtual meeting platform through July 18! 
Not a member? Join now and receive 19 months of membership for the price of 12.

 

 

<blockquote>
"Certainly, I've been anxious about data...I did an experiment, I put a lot of time into it, I'm hoping to get good results...we all know that feeling, right? The stakes are just so different here...this kid's life depends on whether this experiment worked."
--Kiran Musunuru, MD, PhD
</blockquote>
<hr>
One of the highlights of the ASGCT 28th Annual Meeting was&nbsp;<a href="https://www.chop.edu/news/worlds-first-patient-treated-personalized-crispr-gene-editing-therapy-childrens-hospital">the announcement on May 15 of a historic medical breakthrough</a>: a child diagnosed with a rare genetic disorder had been successfully treated for the first time with a customized CRISPR gene editing therapy.
The infant, KJ Muldoon, was born with a rare metabolic disease called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. When he was just six months old, KJ received his personalized therapy at the Children's Hospital of Philadelphia (CHOP), where ASGCT Members Kiran Musunuru, MD, PhD; and Rebecca Ahrens-Nicklas, MD, PhD; led the group of researchers who developed KJ's treatment.
KJ is now growing and thriving. He recently left the hospital where he has spent the majority of his life. And the day after presenting the research that led to this first-of-its-kind development, Dr. Musunuru told us that there was so much more to the story.
Listen to our first episode of Soundbites of the Annual Meeting with Dr. Kiran Musunuru.&nbsp;
Did you attend the 28th Annual Meeting?
<ul>
<li>Watch all sessions, including Dr. Musunuru's presentation, <a href="https://annualmeeting.app.swapcard.com/event/28th-annual-meeting">on demand on the virtual meeting platform</a> through July 18!&nbsp;</li>
<li>Not a member? <a href="https://www.asgct.org/membership/become-a-member">Join now</a> and receive 19 months of membership for the price of 12.</li>
</ul>
&nbsp;
&nbsp;

The American Society of Gene & Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

The American Society of Gene &amp; Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

Advertisement